The University of Sydney has patented P2X7 receptor antagonists reported to be useful for the treatment of stroke, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease, Huntington’s disease, atherosclerosis, diabetic retinopathy and myocardial infarction, among others.

New isoindolines acting as mismatch repair endonuclease PMS2 inhibitors have been reported in a Neophore Ltd. patent as useful for the treatment of cancer.

Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of cancer.

Recent Kallyope Inc. patents report AMP-activated protein kinase (AMPK) activators potentially useful for the treatment of allergy, cancer, depression, diabetes type 2, nutrition disorders, obesity, psoriasis, inflammatory bowel disease, metabolic syndrome, nonalcoholic steatohepatitis, Alzheimer’s and Parkinson’s disease, among others.

Research at Kumquat Biosciences Inc. has led to the development of Hetero-atom containing compounds described as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and (PTPN2; TCPTP) inhibitors and reported to be useful for the treatment of cancer.

The Institute for Drug Research has patented pyrrolidine antiviral compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors.

TYK Medicines Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) binding moieties covalently linked to EGFR (HER1; erbB1) binding moieties reported to be useful for the treatment of cancer, infections, cardiovascular, immunological, inflammatory and metabolic diseases.

Wuhan Zhongcheng Health Bio-Pharm Technology Co. Ltd. has disclosed aromatic amine compounds acting as Bcr-Abl (Bcr-Abl1) kinase inhibitors reported to be useful for the treatment of neurodegeneration, motor neuron disease, muscular dystrophy, autoimmune disease and inflammation, viral infection, prion infection and cancer.

Researchers from INSERM, Samsara Sciences Inc., Sorbonne University and Université Paris Cité have described autophagy inducers reported to be useful for the treatment of cancer, age-related disorders and viral infections.

Janssen Pharmaceutica NV has divulged macrocyclic compounds acting as induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors reported to be useful for the treatment of cancer.